Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder
- Conditions
- Bipolar Disorder
- First Posted Date
- 2004-10-21
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 500
- Registration Number
- NCT00094549
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Saint Petersburg, Russian Federation
Olanzapine in Patients With Borderline Personality Disorder
- Conditions
- Borderline Personality Disorder
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT00091650
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, London, United Kingdom
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 340
- Registration Number
- NCT00090012
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559 or 317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waco, Texas, United States
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2004-08-18
- Last Posted Date
- 2006-07-20
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00089869
- Locations
- 🇺🇸
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.", San Antonio, Texas, United States
🇺🇸"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician., Chula Vista, California, United States
🇺🇸For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Irving, Texas, United States
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
- Conditions
- Schizophrenic Disorders
- First Posted Date
- 2004-07-28
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1205
- Registration Number
- NCT00088491
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2004-07-28
- Last Posted Date
- 2007-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 402
- Registration Number
- NCT00088478
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hrs, EST), or speak with your personal physician., St. Petersburg, Russian Federation
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- Schizophrenic DisordersSchizoaffective Disorder
- Interventions
- First Posted Date
- 2004-07-27
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 931
- Registration Number
- NCT00088465
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma
- First Posted Date
- 2004-07-23
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 60
- Registration Number
- NCT00088205
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rotterdam, Netherlands
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder
- Conditions
- Borderline Personality Disorder
- First Posted Date
- 2004-07-21
- Last Posted Date
- 2006-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 450
- Registration Number
- NCT00088036
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Istanbul, Capa, Turkey
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician, New Haven, Connecticut, United States
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2004-07-21
- Last Posted Date
- 2007-07-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 560
- Registration Number
- NCT00088049
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Salt Lake City, Utah, United States